Nivolumab-Ipilimumab for Gastric/Gastroesophageal Junction Adenocarcinoma

Дата публикации: 15-10-2026 00:00:00

This phase 2 nonrandomized clinical trial reports long-term follow-up results and secondary end points, including event-free survival and overall survival, among patients receiving neoadjuvant nivolumab and ipilimumab followed by surgery for gastric/gastroesophageal junction adenocarcinoma.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Neoadjuvant Stereotactic Ablative Radiotherapy Before Inferior Vena Cava Thrombectomy for Renal Cell Carcinoma	0	7.27	15-10-2026
2	Organ Preservation and QOL After Total Neoadjuvant Treatment in Rectal Cancer	0	7.94	15-10-2026
3	Investigators report promising results from Phase II trial of targeted therapy for rare bile duct cancer	7	8	01-07-2026
4	Perioperative durvalumab plus FLOT improves OS in patients with resectable gastric or GEJ adenocarcinoma	0	9.22	15-09-2026
5	Perioperative durvalumab continues to show clinical benefit in patients with resectable stage IIA to IIIB NSCLC	0	9.27	17-09-2026
6	Five-year survival outcomes with neoadjuvant therapy in melanoma demonstrate that neoadjuvant ICIs exceeded adjuvant benchmarks	0	13.78	13-10-2026
7	Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor	0	25.38	12-10-2026
8	Chemotherapy-Free Regimen of Targeted Agent and Immunotherapeutic Superior to Imatinib and Chemotherapy Among Adult Patients with Ph-positive ALL	0	21.16	16-10-2026
9	Laser Therapy for Sexual Health in Breast Cancer Survivors	0	7.73	15-10-2026
10	Who should be getting annual cancer screenings?	0	6.25	19-10-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 17.25. Источник: www.jamanetwork.com.